Sacchetti M, et al. - Authors examined 40 candidates with moderate to severe dry eye disease (DED) to study the safety and effectiveness of recombinant human nerve growth factor (rhNGF) eye drops in subjects with DED. They categorized the cases: subjects receiving rhNGF eye drops at 20 µg/mL (Group 1: G1) and at 4 µg/mL (Group 2: G2) concentrations. They noted 29 cases experiencing at least one adverse events (AE) (14 in G1 and 15 in G2). Among them, 11 were noticed with at least 1 related AE (8 in G1 and 3 in G2). They recorded significant improvement in the frequency and severity of DED symptoms along with ocular surface damage in both groups, while improvement in tear function was found in G1 only.